Ticona-Perez F, Chen X, Pandiella A, Diaz-Rodriguez E
Cancer Cell Int. 2024; 24(1):275.
PMID: 39098932
PMC: 11299348.
DOI: 10.1186/s12935-024-03466-3.
Dhillon S
Drugs. 2024; 84(4):459-466.
PMID: 38441805
DOI: 10.1007/s40265-024-02004-9.
Bong I, Esa E
Asian Biomed (Res Rev News). 2023; 17(4):152-162.
PMID: 37860676
PMC: 10584387.
DOI: 10.2478/abm-2023-0056.
Ma L, Wei H, Wang K, Meng X, Ni S, Zhou C
Aging (Albany NY). 2022; 14(16):6642-6655.
PMID: 35985770
PMC: 9467405.
DOI: 10.18632/aging.204236.
Kim J, You H, Youn C
BMC Cancer. 2022; 22(1):552.
PMID: 35578316
PMC: 9112459.
DOI: 10.1186/s12885-022-09631-z.
Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy.
Szudy-Szczyrek A, Ahern S, Koziol M, Majowicz D, Szczyrek M, Krawczyk J
Cancers (Basel). 2021; 13(19).
PMID: 34638291
PMC: 8507621.
DOI: 10.3390/cancers13194806.
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
van der Horst H, Gelderloos A, Chamuleau M, Breij E, Zweegman S, Nijhof I
Blood Adv. 2021; 5(8):2165-2172.
PMID: 33885752
PMC: 8095144.
DOI: 10.1182/bloodadvances.2020003731.
Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis.
Wang H, Geng C, Zhou H, Zhang Z, Chen W
Oncol Lett. 2021; 21(4):295.
PMID: 33732371
PMC: 7905534.
DOI: 10.3892/ol.2021.12556.
CD38 and Regulation of the Immune Response Cells in Cancer.
Dwivedi S, Rendon-Huerta E, Ortiz-Navarrete V, Montano L
J Oncol. 2021; 2021:6630295.
PMID: 33727923
PMC: 7936891.
DOI: 10.1155/2021/6630295.
Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function.
Zhou L, Yu W, Jayabalan D, Niesvizky R, Jaffrey S, Huang X
Front Cell Dev Biol. 2021; 8:605989.
PMID: 33392195
PMC: 7773819.
DOI: 10.3389/fcell.2020.605989.
Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins W, Zweegman S, Mutis T, van de Donk N
Front Immunol. 2020; 11:1155.
PMID: 32636838
PMC: 7316960.
DOI: 10.3389/fimmu.2020.01155.
Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.
Higgs J, Lee J, Wang H, Ramani V, Chanda D, Hardy C
Blood Adv. 2018; 1(25):2375-2385.
PMID: 29296887
PMC: 5729616.
DOI: 10.1182/bloodadvances.2017007310.
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A
Blood Adv. 2018; 1(24):2124-2137.
PMID: 29296860
PMC: 5737122.
DOI: 10.1182/bloodadvances.2017008813.
Oncolytic viruses: emerging options for the treatment of breast cancer.
Suryawanshi Y, Zhang T, Essani K
Med Oncol. 2017; 34(3):43.
PMID: 28185165
DOI: 10.1007/s12032-017-0899-0.
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.
Zuch de Zafra C, Ashkenazi A, Darbonne W, Cheu M, Totpal K, Ortega S
Cell Death Dis. 2016; 7(8):e2338.
PMID: 27512959
PMC: 5108326.
DOI: 10.1038/cddis.2016.241.
Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines.
Jian Y, Chen Y, Geng C, Liu N, Yang G, Liu J
Biomed Rep. 2016; 4(6):723-727.
PMID: 27284413
PMC: 4887918.
DOI: 10.3892/br.2016.650.
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
Duru A, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B
PLoS One. 2015; 10(9):e0138248.
PMID: 26378933
PMC: 4574561.
DOI: 10.1371/journal.pone.0138248.
The genetic architecture of multiple myeloma.
Prideaux S, Conway OBrien E, Chevassut T
Adv Hematol. 2014; 2014:864058.
PMID: 24803933
PMC: 3996928.
DOI: 10.1155/2014/864058.
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J
Sci Rep. 2013; 3:3565.
PMID: 24356445
PMC: 3868960.
DOI: 10.1038/srep03565.
Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman M, Reis C, Schuringa J, Vellenga E, Quax W
J Biol Chem. 2013; 289(2):1071-8.
PMID: 24280212
PMC: 3887175.
DOI: 10.1074/jbc.M113.491589.